Endocrinology

In a new study, children exposed to gestational diabetes showed lower FEV1 and increased odds of current asthma at ages 8–9 years.

Results from the ATTAIN-MAINTAIN phase 3 study have displayed orforglipron’s efficacy in maintaining weight loss without major safety concerns.

Explore the latest advancements in diabetes technology, including updates on CGMs and insulin pumps, enhancing patient care and management.

Findings link GLP-1 RA use to reduced HCC risk in patients with type 2 diabetes, with benefits partly attributable to avoiding insulin's potential hepatotoxicity.

Catch up with major trial results, key clinician insights, and more.

This FDA News Month in Review provides a round-up of regulatory decisions from November 2025.

This special edition episode explores the advancements in incretin therapies that defined 2025.

Results from the INTIMET study have shown no significant differences between metformin and placebo in liver, muscle, or adipose tissue insulin resistance.

Shagun Bindlish, MD, emphasizes the urgent need to integrate diabetes and obesity care, addressing their shared metabolic roots for better health outcomes.

Meta-analysis shows semaglutide lowers cardiovascular and kidney risks while supporting safety in adults with chronic kidney disease.

Discover the latest advancements in diabetes technology from November 2025, including Omnipod updates and the new Pivot pump.

The investigational unimolecular GLP-1 and amylin receptor agonist substantially improved weight loss in a phase 2 trial.

Explore the latest findings on GLP-1 drugs, including their impact on Alzheimer's and promising results for type 1 diabetes treatment.

This episode covers the upcoming release of Dexcom's G7 15-day patch and major price cuts for semaglutide.

Eli Lilly and Company’s investigative therapy provided effective and safe weight loss treatment with limited adverse events.

Stay up to date with the groundbreaking FDA decisions, critical trial updates, and more news from the last month.

Based on results from the THRIVE and THRIVE-2 phase 3 studies, this Biologics License Application includes a request for Priority Review.

Alterations in appetite and weight may have influenced abdominal adiposity, as well as inflammatory and cardiometabolic markers.

A secondary analysis of the J-DOIT3 study highlights previously undertreated factors in the progression of diabetic retinopathy in patients with type 2 diabetes.

This episode covers the recent approval of oral semaglutide for T2D and a pre-specified subanalysis of the SELECT trial.

The investigative GLP-1/GCG dual receptor agonist led to a higher proportion of participants achieving HbA1c and body weight improvements from baseline.

A post hoc analysis of the PLIS study has highlighted the comparative effectiveness of glucose levels in achieving prediabetes remission.

GLP-1 RAs may offer benefits beyond adiposity reduction in patients with atherosclerotic cardiovascular disease.

A total of 8 acute and chronic disease factors, including hypertension, obesity, and physical inactivity, compound to increase mortality and CVD risk.